YHR-1902

YHR-1902 is a small molecule drug developed by Yuhan Corp. It has been evaluated in clinical trials for bioequivalence, specifically in comparison to another formulation, YHP1906. The available data indicate that it is an investigational compound with no publicly disclosed mechanism of action or therapeutic target as of the latest updates. Its primary development status is pending, with at least one completed Phase 1 clinical trial focused on healthy volunteers to assess bioequivalence between tablet formulations[1][3][4]. No active indications or detailed pharmacological information are currently available in the public domain.